Amarantus Bioscience Holdings Inc (AMBS)

[JLM27]

If you're wise, in my unsolicited opinion, you're invested in AMBS for MANF, not LymPro, which puts you on roughly a 3 year track or more. While LymPro is certainly a potential moneymaker, MANF is a potential once-in-a-generation drug. If MANF even begins to approach the success of a blockbuster drug like, say, Lipitor, we'll all be fighting over who gets to name their yacht after Gerald.

My point is, if you're in this for MANF, take a step back and reframe your outlook on AMBS. These day to day swings regarding the progression of LymPro that some seem to get so upset about are trivial in the grand scheme of things. Simply let the company execute it's action plan, which appears to be sound, and don't demand a PR every morning and night. I for one like that Gerald doesn't hyper-actively pump the stock like some CEOs I've seen (i.e., NVIV's ex-CEO) because when expectations inevitably meet reality, those stocks implode (I believe NVIV investors have filed suit against the former CEO). In sum, to put things in perspective, LymPro is the Wednesday par 3 tournament, while MANF is the Masters. I try to keep this in mind.